12/20/2013 9:47:06 AM
NATICK, Mass., Dec. 20, 2013 (GLOBE NEWSWIRE) -- Karyopharm Therapeutics Inc. (Nasdaq:KPTI), a clinical-stage pharmaceutical company focused on the discovery and development of novel first-in-class drugs directed against nuclear transport targets for the treatment of cancer and other major diseases, today announced that it has been added to the Russell 3000® and Russell 2000® Indexes as part of Russell Investments' fourth quarter IPO additions, to be effective at the close of the U.S. markets today.
Help employers find you! Check out all the jobs and post your resume.
comments powered by